2000The Journal of Clinical PsychiatryOpen access

Olanzapine-Induced Neutropenia in Patients With History of Clozapine Treatment

Christian J. Teter, John J. Early, Richard J. Frachtling

Open full text 17 citations

Abstract

Article AbstractLetter to the Editor Sir: Olanzapine is an atypical antipsychotic that is similar in structure to clozapine, but has not been associated with hematologic adverse effects until recently. Two case reports from different institutions described patients who experienced agranulocytosis or neutropenia while receiving olanzapine and had previously received clozapine during the course of their illness. In the first patient report, 5 months had passed between clozapine and olanzapine therapy, whereas only 5 days had passed between administration of the 2 agents in the second report. We present 2 patients whose white blood cell (WBC) counts fell while receiving olanzapine therapy after having been previously treated with clozapine. In the first patient, the time period between clozapine therapy and olanzapine therapy was 3 years, and in the second patient, the time period between the 2 medication treatments was 5 days.

Open-access reader

About this research paper

What this paper is about

Article AbstractLetter to the Editor Sir: Olanzapine is an atypical antipsychotic that is similar in structure to clozapine, but has not been associated with hematologic adverse effects until recently. Two case reports from different institutions described patients who experienced agranulocytosis or neutropenia while receiving olanzapine and had previously received clozapine during the course of their illness. In the first patient report, 5 months had passed between clozapine and olanzapine therapy, whereas only 5 days had passed between administration of the 2 agents in the second report. We present 2 patients whose white blood cell (WBC) counts fell while receiving olanzapine therapy after having been previously treated with clozapine. In the first patient, the time period between clozapine therapy and olanzapine therapy was 3 years, and in the second patient, the time period between the 2 medication treatments was 5 days.

Why it matters

OpenAlex reports 17 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Article AbstractLetter to the Editor Sir: Olanzapine is an atypical antipsychotic that is similar in structure to clozapine, but has not been associated with hematologic adverse effects until recently. Two case reports from different institutions described patients who experienced agranulocytosis or neutropenia while receiving olanzapine and had previously received clozapine during the course of their illness. In the first patient report, 5 months had passed between clozapine and olanzapine therapy, whereas only 5 days had passed between administration of the 2 agents in the second report. We present 2 patients whose white blood cell (WBC) counts fell while receiving olanzapine therapy after having been previously treated with clozapine. In the first patient, the time period between clozapine therapy and olanzapine therapy was 3 years, and in the second patient, the time period between the 2 medication treatments was 5 days.

Key concepts: Clozapine, Olanzapine, Neutropenia, Medicine, Atypical antipsychotic, Antipsychotic, Adverse effect, Dopamine antagonist

Related papers

Back to paper searchBrowse research topicsOriginal source
Olanzapine-Induced Neutropenia in Patients With History of Clozapine Treatment — Research Paper | ScholarLens